Structure-based design of mimetics for granulocyte-macrophage colony stimulating factor (GM-CSF)

Cristina Monfardini, Gabriela Canziani, Carmela Plugariu, Thomas Kieber-Emmons, A. Paul Godillot, Joann A. Kwah, Joanna Bajgier, Irwin Chaiken, William V. Williams

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Granulocyte-macrophage colony stimulating factor (GM-CSF) activity has been linked to pro-inflammatory effects in autoimmune syndromes, such as rheumatoid arthritis. Thus GM-CSF mimetics with antagonist activity might play a therapeutic role in these diseases. The human GM-CSF core structure consists of a four α-helix bundle, and GM-CSF activity is controlled by its binding to a two-subunit receptor. A number of residues located on the B and C helices of GM-CSF are postulated to interact with the alpha chain of the GM-CSF receptor (GM-CSFR). Several approaches have been successfully utilized to develop peptide mimetics of this site, including peptides from the native sequence, a peptide derived from a recombinant antibody (rAb) light chain which mimicked GM-CSF receptor binding activity, and structurally guided de novo design. Analysis of the rAb light chain had suggested mimicry of GM-CSF with residues mostly contributed by the CDR I region. Key residues involved in CDR I peptide/GM-CSFR binding were identified by truncation and alteration of individual residues, while the structural elements required to antagonize the biological action of GM-CSF were separately tested in binding and inhibitory activity assays of multiple cyclic analogues. A peptide designed to retain the loop conformation of the CDR I region of the rAb light chain competed with GM-CSF for both antibody and receptor binding, but the role of specific residues in antibody versus receptor binding differed markedly. These studies suggest that structural analysis of peptide mimetics can reveal differences in receptor and antibody binding, perhaps including key interactions that impact binding kinetics. Peptide mimetics of other four-helix bundle cytokines are reviewed, including helical and reverse turn mimetics of helical structures. Use of peptide mimetics coupled with structural and kinetic analysis provides a powerful approach to identifying important receptor-ligand interactions, which implications for rational design of novel therapeutics.

Original languageEnglish (US)
Pages (from-to)2185-2199
Number of pages15
JournalCurrent Pharmaceutical Design
Volume8
Issue number24
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor
Peptides
Granulocyte-Macrophage Colony-Stimulating Factor Receptors
Antibodies
Light
Rheumatoid Arthritis
Cytokines
Ligands
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Monfardini, C., Canziani, G., Plugariu, C., Kieber-Emmons, T., Godillot, A. P., Kwah, J. A., ... Williams, W. V. (2002). Structure-based design of mimetics for granulocyte-macrophage colony stimulating factor (GM-CSF). Current Pharmaceutical Design, 8(24), 2185-2199. https://doi.org/10.2174/1381612023393198

Structure-based design of mimetics for granulocyte-macrophage colony stimulating factor (GM-CSF). / Monfardini, Cristina; Canziani, Gabriela; Plugariu, Carmela; Kieber-Emmons, Thomas; Godillot, A. Paul; Kwah, Joann A.; Bajgier, Joanna; Chaiken, Irwin; Williams, William V.

In: Current Pharmaceutical Design, Vol. 8, No. 24, 2002, p. 2185-2199.

Research output: Contribution to journalReview article

Monfardini, C, Canziani, G, Plugariu, C, Kieber-Emmons, T, Godillot, AP, Kwah, JA, Bajgier, J, Chaiken, I & Williams, WV 2002, 'Structure-based design of mimetics for granulocyte-macrophage colony stimulating factor (GM-CSF)', Current Pharmaceutical Design, vol. 8, no. 24, pp. 2185-2199. https://doi.org/10.2174/1381612023393198
Monfardini, Cristina ; Canziani, Gabriela ; Plugariu, Carmela ; Kieber-Emmons, Thomas ; Godillot, A. Paul ; Kwah, Joann A. ; Bajgier, Joanna ; Chaiken, Irwin ; Williams, William V. / Structure-based design of mimetics for granulocyte-macrophage colony stimulating factor (GM-CSF). In: Current Pharmaceutical Design. 2002 ; Vol. 8, No. 24. pp. 2185-2199.
@article{a8f76feb5ff9487ea4f38729dd71c5b8,
title = "Structure-based design of mimetics for granulocyte-macrophage colony stimulating factor (GM-CSF)",
abstract = "Granulocyte-macrophage colony stimulating factor (GM-CSF) activity has been linked to pro-inflammatory effects in autoimmune syndromes, such as rheumatoid arthritis. Thus GM-CSF mimetics with antagonist activity might play a therapeutic role in these diseases. The human GM-CSF core structure consists of a four α-helix bundle, and GM-CSF activity is controlled by its binding to a two-subunit receptor. A number of residues located on the B and C helices of GM-CSF are postulated to interact with the alpha chain of the GM-CSF receptor (GM-CSFR). Several approaches have been successfully utilized to develop peptide mimetics of this site, including peptides from the native sequence, a peptide derived from a recombinant antibody (rAb) light chain which mimicked GM-CSF receptor binding activity, and structurally guided de novo design. Analysis of the rAb light chain had suggested mimicry of GM-CSF with residues mostly contributed by the CDR I region. Key residues involved in CDR I peptide/GM-CSFR binding were identified by truncation and alteration of individual residues, while the structural elements required to antagonize the biological action of GM-CSF were separately tested in binding and inhibitory activity assays of multiple cyclic analogues. A peptide designed to retain the loop conformation of the CDR I region of the rAb light chain competed with GM-CSF for both antibody and receptor binding, but the role of specific residues in antibody versus receptor binding differed markedly. These studies suggest that structural analysis of peptide mimetics can reveal differences in receptor and antibody binding, perhaps including key interactions that impact binding kinetics. Peptide mimetics of other four-helix bundle cytokines are reviewed, including helical and reverse turn mimetics of helical structures. Use of peptide mimetics coupled with structural and kinetic analysis provides a powerful approach to identifying important receptor-ligand interactions, which implications for rational design of novel therapeutics.",
author = "Cristina Monfardini and Gabriela Canziani and Carmela Plugariu and Thomas Kieber-Emmons and Godillot, {A. Paul} and Kwah, {Joann A.} and Joanna Bajgier and Irwin Chaiken and Williams, {William V.}",
year = "2002",
doi = "10.2174/1381612023393198",
language = "English (US)",
volume = "8",
pages = "2185--2199",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "24",

}

TY - JOUR

T1 - Structure-based design of mimetics for granulocyte-macrophage colony stimulating factor (GM-CSF)

AU - Monfardini, Cristina

AU - Canziani, Gabriela

AU - Plugariu, Carmela

AU - Kieber-Emmons, Thomas

AU - Godillot, A. Paul

AU - Kwah, Joann A.

AU - Bajgier, Joanna

AU - Chaiken, Irwin

AU - Williams, William V.

PY - 2002

Y1 - 2002

N2 - Granulocyte-macrophage colony stimulating factor (GM-CSF) activity has been linked to pro-inflammatory effects in autoimmune syndromes, such as rheumatoid arthritis. Thus GM-CSF mimetics with antagonist activity might play a therapeutic role in these diseases. The human GM-CSF core structure consists of a four α-helix bundle, and GM-CSF activity is controlled by its binding to a two-subunit receptor. A number of residues located on the B and C helices of GM-CSF are postulated to interact with the alpha chain of the GM-CSF receptor (GM-CSFR). Several approaches have been successfully utilized to develop peptide mimetics of this site, including peptides from the native sequence, a peptide derived from a recombinant antibody (rAb) light chain which mimicked GM-CSF receptor binding activity, and structurally guided de novo design. Analysis of the rAb light chain had suggested mimicry of GM-CSF with residues mostly contributed by the CDR I region. Key residues involved in CDR I peptide/GM-CSFR binding were identified by truncation and alteration of individual residues, while the structural elements required to antagonize the biological action of GM-CSF were separately tested in binding and inhibitory activity assays of multiple cyclic analogues. A peptide designed to retain the loop conformation of the CDR I region of the rAb light chain competed with GM-CSF for both antibody and receptor binding, but the role of specific residues in antibody versus receptor binding differed markedly. These studies suggest that structural analysis of peptide mimetics can reveal differences in receptor and antibody binding, perhaps including key interactions that impact binding kinetics. Peptide mimetics of other four-helix bundle cytokines are reviewed, including helical and reverse turn mimetics of helical structures. Use of peptide mimetics coupled with structural and kinetic analysis provides a powerful approach to identifying important receptor-ligand interactions, which implications for rational design of novel therapeutics.

AB - Granulocyte-macrophage colony stimulating factor (GM-CSF) activity has been linked to pro-inflammatory effects in autoimmune syndromes, such as rheumatoid arthritis. Thus GM-CSF mimetics with antagonist activity might play a therapeutic role in these diseases. The human GM-CSF core structure consists of a four α-helix bundle, and GM-CSF activity is controlled by its binding to a two-subunit receptor. A number of residues located on the B and C helices of GM-CSF are postulated to interact with the alpha chain of the GM-CSF receptor (GM-CSFR). Several approaches have been successfully utilized to develop peptide mimetics of this site, including peptides from the native sequence, a peptide derived from a recombinant antibody (rAb) light chain which mimicked GM-CSF receptor binding activity, and structurally guided de novo design. Analysis of the rAb light chain had suggested mimicry of GM-CSF with residues mostly contributed by the CDR I region. Key residues involved in CDR I peptide/GM-CSFR binding were identified by truncation and alteration of individual residues, while the structural elements required to antagonize the biological action of GM-CSF were separately tested in binding and inhibitory activity assays of multiple cyclic analogues. A peptide designed to retain the loop conformation of the CDR I region of the rAb light chain competed with GM-CSF for both antibody and receptor binding, but the role of specific residues in antibody versus receptor binding differed markedly. These studies suggest that structural analysis of peptide mimetics can reveal differences in receptor and antibody binding, perhaps including key interactions that impact binding kinetics. Peptide mimetics of other four-helix bundle cytokines are reviewed, including helical and reverse turn mimetics of helical structures. Use of peptide mimetics coupled with structural and kinetic analysis provides a powerful approach to identifying important receptor-ligand interactions, which implications for rational design of novel therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=0036402032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036402032&partnerID=8YFLogxK

U2 - 10.2174/1381612023393198

DO - 10.2174/1381612023393198

M3 - Review article

VL - 8

SP - 2185

EP - 2199

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 24

ER -